Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer

2014 ◽  
Vol 10 (2) ◽  
pp. 195-209 ◽  
Author(s):  
Haïdar Saadoun ◽  
Pierre-Jean Lamy ◽  
Simon Thezenas ◽  
Stéphane Pouderoux ◽  
Frédéric Bibeau ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Early Breast Cancer ◽  
Adjuvant Treatment ◽  
Treatment Decision ◽  
Prognostic Impact ◽  
Treatment Decision Making ◽  
Pai 1

Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2− pN0 early breast cancers

2017 ◽  
Vol 165 (3) ◽  
pp. 611-621 ◽  
Author(s):  
Marie Viala ◽  
Marie Alexandre ◽  
Simon Thezenas ◽  
Pierre-Jean Lamy ◽  
Aurélie Maran-Gonzalez ◽  
...  
Keyword(s):  
Decision Making ◽  
Adjuvant Treatment ◽  
Treatment Decision ◽  
Prognostic Impact ◽  
Breast Cancers ◽  
Treatment Decision Making ◽  
Pai 1

Gene Expression Assay in the Management of Early Breast Cancer

2020 ◽  
Vol 27 (17) ◽  
pp. 2826-2839 ◽  
Author(s):  
Roberta Caputo ◽  
Daniela Cianniello ◽  
Antonio Giordano ◽  
Michela Piezzo ◽  
Maria Riemma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Decision Making ◽  
Adjuvant Chemotherapy ◽  
Early Breast Cancer ◽  
Treatment Decision ◽  
Endocrine Treatment ◽  
Expression Ratio ◽  
Treatment Decision Making ◽  
Low Sensitivity

The addition of adjuvant chemotherapy to hormonal therapy is often considered questionable in patients with estrogen receptor-positive early breast cancer. Low risk of disease relapse after endocrine treatment alone and/or a low sensitivity to chemotherapy are reasons behind not all patients benefit from chemotherapy. Most of the patients could be exposed to unnecessary treatment- related adverse events and health care costs when treatment decision-making is based only on classical clinical histological features. Gene expression profile has been developed to refine physician’s decision-making process and to tailor personalized treatment to patients. In particular, these tests are designed to spare patients the side effects of unnecessary treatment, and ensure that adjuvant chemotherapy is correctly recommended to patients with early breast cancer. In this review, we will discuss the main diagnostic tests and their potential clinical applications (Oncotype DX, MammaPrint, PAM50/Prosigna, EndoPredict, MapQuant Dx, IHC4, and Theros-Breast Cancer Gene Expression Ratio Assay).

Population-based evaluation of 21-gene assay in treatment decision making for early breast cancer in Ontario.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 583-583 ◽  
Author(s):  
Mark Norman Levine ◽  
Brandy Lynn Cochrane ◽  
Jim A. Julian ◽  
Maureen E. Trudeau ◽  
Andrea Eisen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Early Breast Cancer ◽  
Treatment Decision ◽  
Population Based ◽  
Treatment Decision Making ◽  
Gene Assay

scholarly journals Contribution of the Prosigna® (PAM50) Gene Signature Assay as a New-generation Genomic Test for Treatment Decision-making in Early Breast Cancer

2015 ◽  
Vol 11 (2) ◽  
pp. 85 ◽  
Author(s):  
Nadia Harbeck ◽  
Rachel Wuerstlein ◽  
Karl Sotlar ◽  
◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Early Breast Cancer ◽  
Cancer Biology ◽  
Treatment Decision ◽  
Gene Signature ◽  
Treatment Decision Making ◽  
Prognostic Gene ◽  
Prognostic Gene Signature ◽  
Post Menopausal

The Prosigna® Breast Cancer Prognostic Gene Signature Assay is based on the characterisation of 50 genes relevant to breast cancer biology and provides intrinsic subtype identification based on the individual tumour biology, a prognostic risk of recurrence (ROR) score and a risk group classification, for each individual patient tested. The Prosigna assay is indicated for post-menopausal women with early-stage hormone receptor-positive breast cancer with or without nodal involvement. Running on the NanoString nCounter® DX Analysis system, which allows direct digital counting of target molecules, the assay offers a simple, reproducible and reliable method to profile many genes simultaneously with high sensitivity and precision. The Prosigna Breast Cancer Prognostic Gene Signature Assay has received 510(k) clearance from the US Food and Drug Administration. It has also received a CE mark and is available for use, among other geographical areas, in the EU, Israel and parts of the Middle East, through qualified local pathology laboratories. The de-centralised testing enables timely result delivery and direct interaction between the laboratory pathologists and treating physicians. The analytical reproducibility, precision and robustness of Prosigna have been demonstrated. Moreover, it has been clinically validated in two independent prospectiveretrospective studies using >2,400 samples from post-menopausal patients enrolled in the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG 8) and Arimidex, Tamoxifen Alone or Combined (ATAC) trials (Level 1B Evidence). These validation studies show that Prosigna identifies a clinically relevant low-risk subgroup among both node-negative and node-positive patients with 1-3 involved lymph nodes. Moreover, the ROR score predicts risk of late distant recurrence as well as for high risk of local recurrence. Prosigna thus can offer clinically relevant information, which may help guide treatment decision-making in early breast cancer.

Sign in / Sign up

Export Citation Format

Share Document